[ Price : $8.95]
House Energy and Commerce Committee ranking member Frank Pallone asks the Government Accountability Office to analyze how FDA paid...[ Price : $8.95]
A group of academic and public health experts urges FDA to embrace greater transparency, scientific independence and regulatory co...[ Price : $8.95]
FDA converts the accelerated approval of Eli Lilly's Retevmo (selpercatinib) into a traditional approval for treating adult and pe...[ Price : $8.95]
FDA finalizes updated guidance for industry outlining current recommendations for demonstrating bioequivalence of generic topical ...[ Price : $8.95]
The House Energy and Commerce Subcommittee on Health plans a hearing 7/15 to examine how FDA can help strengthen U.S. leadership i...[ Price : $8.95]
DTC Perspectives CEO Bob Ehrlich warns that an upcoming FDA proposal to eliminate the adequate provision standard could amount to ...[ Price : $8.95]
Ascelia Pharma pushes back against FDA's recent public release of a Complete Response Letter for its MRI contrast agent Orviglance...[ Price : $8.95]
GSK says its PD-1 inhibitor Jemperli (dostarlimab) achieved the primary endpoint in a registrational Phase 2 trial in patients wit...